UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 31,866 Shares of IDEAYA Biosciences, Inc. $IDYA

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC cut its holdings in shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) by 18.2% during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 143,285 shares of the company’s stock after selling 31,866 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned about 0.16% of IDEAYA Biosciences worth $5,340,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in IDYA. Royal Bank of Canada raised its stake in shares of IDEAYA Biosciences by 30.1% during the first quarter. Royal Bank of Canada now owns 122,460 shares of the company’s stock valued at $2,006,000 after acquiring an additional 28,322 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in IDEAYA Biosciences by 8.2% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 57,044 shares of the company’s stock valued at $938,000 after purchasing an additional 4,308 shares during the period. Millennium Management LLC increased its holdings in IDEAYA Biosciences by 345.2% in the first quarter. Millennium Management LLC now owns 547,637 shares of the company’s stock valued at $8,970,000 after purchasing an additional 424,625 shares during the period. American Century Companies Inc. raised its position in IDEAYA Biosciences by 862.7% during the 2nd quarter. American Century Companies Inc. now owns 114,644 shares of the company’s stock worth $2,410,000 after purchasing an additional 102,736 shares during the last quarter. Finally, Norges Bank bought a new position in IDEAYA Biosciences during the 2nd quarter worth $643,000. 98.29% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Citigroup reiterated a “market outperform” rating on shares of IDEAYA Biosciences in a research report on Tuesday, September 1st. Weiss Ratings restated a “sell (d-)” rating on shares of IDEAYA Biosciences in a research report on Friday, July 17th. Wedbush upped their target price on IDEAYA Biosciences from $58.00 to $60.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Jefferies Financial Group reiterated a “buy” rating on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Finally, Citizens Jmp restated a “market outperform” rating and set a $42.00 price target on shares of IDEAYA Biosciences in a report on Tuesday, September 1st. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $52.46.

IDEAYA Biosciences Stock Down 2.6%

Shares of NASDAQ IDYA opened at $38.84 on Wednesday. The firm has a market cap of $3.41 billion, a PE ratio of -20.02 and a beta of -0.07. IDEAYA Biosciences, Inc. has a 12-month low of $23.53 and a 12-month high of $42.68. The company’s fifty day simple moving average is $37.70 and its 200 day simple moving average is $33.59.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($1.22) earnings per share for the quarter, missing the consensus estimate of ($1.06) by ($0.16). IDEAYA Biosciences had a negative net margin of 75.93% and a negative return on equity of 16.73%. The company had revenue of $8.86 million during the quarter, compared to the consensus estimate of $8.02 million. During the same period last year, the firm posted ($0.88) earnings per share. The company’s revenue for the quarter was up 8800.0% on a year-over-year basis. On average, equities analysts predict that IDEAYA Biosciences, Inc. will post -4.38 earnings per share for the current year.

Insider Activity

In other news, CAO Andres Ruiz Briseno sold 9,550 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $40.01, for a total value of $382,095.50. Following the completion of the sale, the chief accounting officer directly owned 26,466 shares in the company, valued at $1,058,904.66. This trade represents a 26.52% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. 4.70% of the stock is owned by company insiders.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences is a clinical-stage precision oncology company dedicated to the discovery and development of novel therapies that exploit synthetic lethality in cancer cells. By targeting key DNA damage response pathways, the company aims to selectively kill tumor cells exhibiting specific genetic vulnerabilities while sparing healthy tissue. IDEAYA’s pipeline includes small-molecule inhibitors designed to address underserved tumor types, and its lead programs are advancing through Phase 1 and Phase 2 clinical trials in multiple oncology indications.

Central to IDEAYA’s approach is its Modular Approach to Precision (MAP) platform, which integrates proprietary genomic and functional screening technologies to identify critical cancer-specific dependencies.